Cabaletta Bio, Inc. (CABA)
NASDAQ: CABA · Real-Time Price · USD
2.995
+0.045 (1.53%)
Jan 27, 2026, 12:54 PM EST - Market open
Cabaletta Bio Employees
As of September 30, 2025, Cabaletta Bio had 151 total employees, including 148 full-time and 3 part-time employees. The number of employees decreased by 4 or -2.58% compared to the same quarter last year.
Employees
151
Change
-4
Growth
-2.58%
Revenue / Employee
n/a
Profits / Employee
-$1,049,821
Market Cap
288.31M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 151 | -4 | -2.58% | 148 | 3 |
| Jun 30, 2025 | 170 | 32 | 23.19% | 167 | 3 |
| Mar 31, 2025 | 167 | 47 | 39.17% | 163 | 4 |
| Dec 31, 2024 | 164 | 61 | 59.22% | 161 | 3 |
| Sep 30, 2024 | 155 | 61 | 64.89% | 154 | 1 |
| Jun 30, 2024 | 138 | 59 | 74.68% | 136 | 2 |
| Mar 31, 2024 | 120 | 53 | 79.10% | 118 | 2 |
| Dec 31, 2023 | 103 | 43 | 71.67% | 101 | 2 |
| Sep 30, 2023 | 94 | 35 | 59.32% | 92 | 2 |
| Jun 30, 2023 | 79 | 21 | 36.21% | 77 | 2 |
| Mar 31, 2023 | 67 | 10 | 17.54% | 66 | 1 |
| Dec 31, 2022 | 60 | 6 | 11.11% | 58 | 2 |
| Sep 30, 2022 | 59 | 12 | 25.53% | 57 | 2 |
| Jun 30, 2022 | 58 | 19 | 48.72% | 57 | 1 |
| Mar 31, 2022 | 57 | 21 | 58.33% | 56 | 1 |
| Dec 31, 2021 | 54 | 20 | 58.82% | 53 | 1 |
| Sep 30, 2021 | 47 | 15 | 46.88% | 46 | 1 |
| Jun 30, 2021 | 39 | 8 | 25.81% | 38 | 1 |
| Mar 31, 2021 | 36 | 7 | 24.14% | 35 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Cellectis | 222 |
| Puma Biotechnology | 172 |
| X4 Pharmaceuticals | 143 |
| Fractyl Health | 101 |
| Rezolute | 71 |
| Larimar Therapeutics | 65 |
| Atea Pharmaceuticals | 56 |
| Achieve Life Sciences | 25 |
CABA News
- 1 hour ago - Cabaletta Bio: Do You Buy With The Insiders? - Seeking Alpha
- 15 days ago - Cabaletta Bio Announces 2026 Strategic Priorities - GlobeNewsWire
- 15 days ago - IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms - Business Wire
- 7 weeks ago - Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December - GlobeNewsWire
- 3 months ago - Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025 - GlobeNewsWire
- 3 months ago - Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant - GlobeNewsWire